SCHEMBL4501049

SCHEMBL4501049

CCOC(=O)C1CCC(=O)N(C(CC)C(=O)O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
MAPT P10636 3/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA3 P07451 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA5A P35218 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA13 Q8N1Q1 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CA5B Q9Y2D0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491631 0.90 LMNA (0.56) KDM4EALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL4496231 0.85 ALDH1A1 (0.46) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL4500162 0.76 LMNA (0.61) KDM4EALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL1877216 0.73 LMNA (0.75) ALDH1A1KMT2ALMNACA12CA1
SCHEMBL1747843 0.73 LMNA (0.75) ALDH1A1KMT2ALMNACA12CA1
SCHEMBL2079098 0.73 LMNA (0.75) ALDH1A1KMT2ALMNACA12CA1
SCHEMBL5483 0.70 ALDH1A1 (0.51) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL13116800 0.69 MAPT (0.62) KDM4EALDH1A1SMN1; SMN2MAPTMEN1
SCHEMBL21313417 0.69 LMNA (0.69) ALDH1A1MEN1KMT2ANPC1LMNA
SCHEMBL1878246 0.69 LMNA (0.69) ALDH1A1MEN1KMT2ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040132717-A1 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB, S.A. (BE) 2004-07-08 US claimed
EP-1395560-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2004-03-10 EP claimed
WO-2002094787-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2002-11-28 WO claimed
US-7473697-B2 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB S.A. (BE) 2009-01-06 US disclosed
US-7473697-B2 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB S.A. (BE) 2009-01-06 US disclosed
US-7473697-B2 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB S.A. (BE) 2009-01-06 US disclosed
US-20060258704-A1 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders MICHEL PHILIPPE 2006-11-16 US disclosed
US-7087596-B2 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB, S.A. (BE) 2006-08-08 US disclosed
US-20040132717-A1 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB, S.A. (BE) 2004-07-08 US disclosed
EP-1395560-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2004-03-10 EP disclosed
WO-2002094787-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132717-A1 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders GABRA6, GABRA2, HCAR2 KDM4E 965/4885ALDH1A1 131/4885SMN1; SMN2 683/4885
US-20060258704-A1 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders GABRA6, HCAR2, GABRA2 KDM4E 910/4885ALDH1A1 139/4885SMN1; SMN2 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.